Diversified Trust’s Vanda Pharmaceuticals VNDA Stock Holding History

Diversified Trust’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,138	Closed	-$56.9K	–	998
2024 Q3	$56.9K	Buy	12,138 +230	+2%	+$1.23K	﹤0.01%	888
2024 Q2	$67.3K	Sell	11,908 -50,645	-81%	-$262K	﹤0.01%	843
2024 Q1	$257K	Buy	62,553 +1,751	+3%	+$7.01K	0.01%	690
2023 Q4	$257K	Sell	60,802 -8,224	-12%	-$33.2K	0.01%	710
2023 Q3	$298K	Buy	69,026 +22,065	+47%	+$123K	0.01%	620
2023 Q2	$309K	Buy	46,961 +26,605	+131%	+$171K	0.01%	614
2023 Q1	$138K	Sell	20,356 -6,176	-23%	-$43.4K	0.01%	777
2022 Q4	$196K	Buy	26,532 +11,432	+76%	+$111K	0.01%	728
2022 Q3	$149K	Buy	+15,100	New	+$159K	0.01%	722
2021 Q1	–	Sell	-10,239	Closed	-$135K	–	858
2020 Q4	$135K	Hold	10,239	–	–	0.01%	697
2020 Q3	$99K	Buy	+10,239	New	+$109K	﹤0.01%	611

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Diversified Trust's VNDA Position: Q4 2024 in Review

Diversified Trust sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 12,138 shares — an estimated $56.9K sold.

Diversified Trust first reported a position in VNDA in Q3 2020 and held it in 11 quarters. The position peaked at $309K in Q2 2023. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

Diversified Trust reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Diversified Trust sold 12,138 Vanda Pharmaceuticals shares in Q4 2024, an estimated $56.9K.
Diversified Trust first reported a position in Vanda Pharmaceuticals in Q3 2020 and held it in 11 quarters.
Diversified Trust's Vanda Pharmaceuticals position peaked at $309K in Q2 2023.
146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Diversified Trust's 13F filing for Q4 2024, filed 7 Jan 2025.